CPIX vs. BIOR, NRSN, BFRG, MEIP, GDTC, SYBX, INDP, ONTX, ONCT, and YMTX
Should you be buying Cumberland Pharmaceuticals stock or one of its competitors? The main competitors of Cumberland Pharmaceuticals include Biora Therapeutics (BIOR), NeuroSense Therapeutics (NRSN), Bullfrog AI (BFRG), MEI Pharma (MEIP), CytoMed Therapeutics (GDTC), Synlogic (SYBX), Indaptus Therapeutics (INDP), Onconova Therapeutics (ONTX), Oncternal Therapeutics (ONCT), and Yumanity Therapeutics (YMTX). These companies are all part of the "pharmaceutical preparations" industry.
Cumberland Pharmaceuticals (NASDAQ:CPIX) and Biora Therapeutics (NASDAQ:BIOR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment, community ranking and earnings.
Cumberland Pharmaceuticals received 183 more outperform votes than Biora Therapeutics when rated by MarketBeat users. However, 66.67% of users gave Biora Therapeutics an outperform vote while only 45.28% of users gave Cumberland Pharmaceuticals an outperform vote.
Cumberland Pharmaceuticals has a beta of 0.16, meaning that its stock price is 84% less volatile than the S&P 500. Comparatively, Biora Therapeutics has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500.
15.5% of Cumberland Pharmaceuticals shares are held by institutional investors. Comparatively, 43.7% of Biora Therapeutics shares are held by institutional investors. 43.3% of Cumberland Pharmaceuticals shares are held by company insiders. Comparatively, 23.2% of Biora Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Cumberland Pharmaceuticals had 46 more articles in the media than Biora Therapeutics. MarketBeat recorded 46 mentions for Cumberland Pharmaceuticals and 0 mentions for Biora Therapeutics. Biora Therapeutics' average media sentiment score of 0.00 beat Cumberland Pharmaceuticals' score of -0.18 indicating that Biora Therapeutics is being referred to more favorably in the news media.
Cumberland Pharmaceuticals has higher revenue and earnings than Biora Therapeutics. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Biora Therapeutics, indicating that it is currently the more affordable of the two stocks.
Biora Therapeutics has a net margin of 0.00% compared to Cumberland Pharmaceuticals' net margin of -15.87%. Cumberland Pharmaceuticals' return on equity of 6.84% beat Biora Therapeutics' return on equity.
Summary
Cumberland Pharmaceuticals beats Biora Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Cumberland Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CPIX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CPIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cumberland Pharmaceuticals Competitors List
Related Companies and Tools
